New research from Stockholm University and Karolinska Institutet shows that viruses interact with proteins in the biological fluids of their host which results in a layer of proteins on the viral surface. This coat of proteins makes the virus more infectious and facilitates the formation of plaques characteristic of neurodegenerative diseases such as Alzheimer’s disease.
Are viruses dead or alive? Well… both. Viruses can only reproduce inside living cells and exploit the cellular machinery of their host to their benefit. However, before entering a host cell, viruses are just nanometer-sized particles, very similar to artificial nanoparticles used in medical applications for diagnosis and therapy. Scientists from Stockholm University and Karolinska Institutet have found that viruses and nanoparticles share another important property; they both become covered by a layer of proteins when they encounter the biological fluids of their host before they find their target cell. This layer of proteins on the surface influence their biological activity significantly.
“Imagine a tennis ball falling into a bowl of milk and cereals. The ball is immediately covered by the sticky particles in the mix and they remain on the ball when you take it out of the bowl. The same thing happens when a virus gets in contact with blood or lung fluids that contain thousands of proteins. Many of these proteins immediately stick to the viral surface forming a so-called protein corona”, Kariem Ezzat of Stockholm University and Karolinska Institutet explains.
Kariem Ezzat and his colleagues studied the protein corona of respiratory syncytial virus (RSV) in different biological fluids. RSV is the most common cause of acute lower respiratory tract infections in young children worldwide, leading up to 34 million cases and 196,000 fatalities each year. “The protein corona signature of RSV in the blood is very different from that in lung fluids. It is also different between humans and other species such as rhesus macaque monkeys, which also can be infected with RSV”, Kariem Ezzat says. “The virus remains unchanged on the genetic level. It just acquires different identities by accumulating different protein coronae on its surface depending on its environment. This makes it possible for the virus to use extracellular host factors for its benefit, and we’ve shown that many of these different coronae make RSV more infectious.”
The researchers from Stockholm University and Karolinska Institutet have also found that viruses such as RSV and herpes simplex virus type 1 (HSV-1) can bind a special class of proteins called amyloid proteins. Amyloid proteins aggregate into plaques that play a part in Alzheimer’s disease where they lead to neuronal cell death. The mechanism behind the connection between viruses and amyloid plaques has been hard to find till now, but Kariem Ezzat and his colleagues found that HSV-1 is able to accelerate the transformation of soluble amyloid proteins into thread-like structures that constitute the amyloid plaques. In animal models of Alzheimer’s disease, they saw that mice developed the disease within 48 hours of infection in the brain. In absence of an HSV-1 infection the process normally takes several months.
“The novel mechanisms described in our paper can have an impact not only on understanding new factors determining how infectious a virus is, but also on devising new ways to design vaccines. In addition, describing a physical mechanism that links viral and amyloid causes of disease adds weight to the increasing research interest in the role of microbes in neurodegenerative disorders such as Alzheimer’s disease and opens up new avenues for treatments.”, Kariem Ezzat of Stockholm University and Karolinska Institutet says.
Learn more: Coat of proteins makes viruses more infectious and links them to Alzheimer’s disease
The Latest on: Neurodegenerative diseases
[google_news title=”” keyword=”neurodegenerative diseases” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Neurodegenerative diseases
- The truth behind ApoE4 gene variant and your risk of developing Alzheimer’s Diseaseon May 8, 2024 at 2:07 am
Researchers have found evidence suggesting that lifestyle factors may play a pivotal role in mitigating the risk of Alzheimer's disease ...
- Research suggests tear fluid testing as promising method for Huntington’s Disease monitoringon May 7, 2024 at 2:15 pm
Huntington's disease (HD) is an autosomal-dominant, fully-penetrant, neurodegenerative disease that most commonly affects adults during middle age.
- Alzheimer's Variant May Cause Distinct Form of the Diseaseon May 6, 2024 at 8:53 pm
He holds a patent for markers of synaptopathy in neurodegenerative disease. Co-authors reported relationships with pharmaceutical companies and other organizations. Huang reported a relationship with ...
- MD Anderson gets $20M gift to boost neurodegenerative researchon May 6, 2024 at 2:54 pm
The University of Texas MD Anderson Cancer Center in Houston has received a $20 million gift from a longtime donor that will go toward advancing research on Alzheimer's and other types of ...
- Neural Compass May Lead to Insights into Parkinson’s and Alzheimer’s Diseaseson May 6, 2024 at 1:20 pm
Internal neural compass which the human brain uses to orientate itself in space and navigate through the environment has been identified.
- Scientists Finally Explain Puzzling Link Between Depression and Cardiovascular Diseaseon May 4, 2024 at 8:58 pm
Gene expression analysis of blood identifies a functional group of genes linked to both depression and cardiovascular disease. Depression and cardiovascular disease (CVD) pose significant challenges ...
- Leprosy drug may be effective in Huntington's disease, study suggestson May 3, 2024 at 6:16 am
A preclinical study from Karolinska Institutet offers hope for treating severe neurodegenerative diseases with an existing drug. The study suggests that the leprosy drug clofazimine may be effective ...
- To save lives, the FDA must change how it evaluates rare disease treatmentson May 1, 2024 at 9:45 am
To get a green light from the FDA using the traditional approval process, new drugs must undergo two randomized, placebo-controlled clinical trials that confirm safety and clinical benefit — usually ...
- Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseaseson May 1, 2024 at 3:45 am
Coya Therapeutics is a biotech company developing therapies for neurodegenerative diseases. Read why I deem COYA stock as a good speculative buy.
- Synthetic nanomaterial could be an effective tool for treating neurodegenerative diseaseson April 26, 2024 at 1:44 am
A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer's and other neurodegenerative diseases.
via Bing News